Table 2.
Mean combination index values of NVP-AEW541 plus gemcitabine or afatinib in pancreatic cancer cell lines (three independent experiments)
|
Cell line |
Mean Combination index (range, effect) |
|||
|---|---|---|---|---|
| NVP-AEW541+GEM | p-value | NVP-AEW541+Afatinib | p-value | |
| BxPc-3 |
0.96 (0.92–1.08, Additive) |
p=0.54 |
0.34 (0.29–0.44, Synergism) |
p<0.05 |
| AsPc-1 |
0.91 (0.86–0.95, Additive) |
p<0.05 |
0.75 (0.68–0.84, Moderate Synergism) |
p<0.05 |
| FA-6 |
1.22 (1.07–1.33, Moderate antagonism) |
p<0.05 |
0.8 (0.68–0.94, Moderate Synergism) |
p=0.057 |
| PANC-1 |
0.7 (0.56–0.84, Synergism) |
p<0.05 |
0.73 (0.61–0.86, Moderate Synergism) |
p<0.05 |
| Capan-1 |
1.43 (1.31–1.52, Moderate antagonism) |
p<0.05 |
0.9 (0.81–1.05, Slight Synergism/Additive) |
p=0.34 |
| MiaPaca-2 |
1.14 (1.02–1.27, Slight antagonism) |
p=0.11 |
0.84 (0.78–0.91, Moderate Synergism) |
p<0.05 |
| PT45 | 1.09 (0.92–1.23, Additive) | p=0.36 | 1.44 (Moderate antagonism) | p<0.05 |
Interpretation of the results was based on the proposed descriptions for presenting the degrees of antagonism or synergism by Calcusyn software. P values indicate level of statistical significance compared with a combination index value of 1.